Abou D, DiNardo CD. The role of enasidenib in the treatment of mutant IDH2 acute myeloid leukemia. Ther Adv Hematol 2018;9(7):163-73. Abstract
Altman JK et al. Phase 1 study of quizartinib in combination with induction and consolidation chemotherapy in patients with newly diagnosed acute myeloid leukemia. Am J Hematol 2018;93(2):213-21. Abstract
Boddu PC et al. Validation of the 2017 European LeukemiaNet classification for acute myeloid leukemia with NPM1 and FLT3-internal tandem duplication genotypes. Cancer 2019;125(7):1091-100. Abstract
Boddu PC et al. Characteristics and outcomes of older patients with secondary acute myeloid leukemia according to treatment approach. Cancer 2017;123(16):3050-60. Abstract
Brunner AM et al. Isocitrate dehydrogenase 1 and 2 mutations, 2-hydroxyglutarate levels, and response to standard chemotherapy for patients with newly diagnosed acute myeloid leukemia. Cancer 2019;125(4):541-9. Abstract
DiNardo CD. Enasidenib for patients with relapsed acute myeloid leukemia and the IDH2 mutation. Clin Adv Hematol Oncol 2018;16(4):247-9. Abstract
DiNardo CD. Ivosidenib in IDH1-mutated acute myeloid leukemia. N Engl J Med 2018;379(12):1186. Abstract
DiNardo CD et al. Mutant IDH1 inhibitor ivosidenib (IVO; AG-120) in combination with azacitidine (AZA) for newly diagnosed acute myeloid leukemia (ND AML). Proc ASCO 2019;Abstract 7011.
DiNardo CD et al. Venetoclax combined with decitabine or azacitidine in treatment-naïve, elderly patients with acute myeloid leukemia. Blood 2019;133(1):7-17. Abstract
DiNardo CD et al. Clinical experience with the BCL2-inhibitor venetoclax in combination therapy for relapsed and refractory acute myeloid leukemia and related myeloid malignancies. Am J Hematol 2018;93(3):401-7. Abstract
DiNardo CD et al. Durable remissions with ivosidenib in IDH1-mutated relapsed or refractory AML. N Engl J Med 2018;378(25):2386-98. Abstract
DiNardo CD et al. Safety and preliminary efficacy of venetoclax with decitabine or azacitidine in elderly patients with previously untreated acute myeloid leukaemia: A non-randomised, open-label, phase 1b study. Lancet Oncol 2018;19(2):216-28. Abstract
DiNardo CD, Lachowiez C. Acute myeloid leukemia: From mutation profiling to treatment decisions. Curr Hematol Malig Rep 2019;14(5):386-94. Abstract
Guerra VA et al. Venetoclax-based therapies for acute myeloid leukemia. Best Pract Res Clin Haematol 2019;32(2):145-53. Abstract
Montalban-Bravo G et al. NPM1 mutations define a specific subgroup of MDS and MDS/MPN patients with favorable outcomes with intensive chemotherapy. Blood Adv 2019;3(6):922-33. Abstract
Montalban-Bravo G, DiNardo CD. The role of IDH mutations in acute myeloid leukemia. Future Oncol 2018;14(10):979-93. Abstract
Ok CY et al. Persistent IDH1/2 mutations in remission can predict relapse in patients with acute myeloid leukemia. Haematologica 2019;104(2):305-11. Abstract
Patel SS et al. High NPM1 mutant allele burden at diagnosis correlates with minimal residual disease at first remission in de novo acute myeloid leukemia. Am J Hematol 2019;94(8):921-8. Abstract
Pollyea DA et al. Enasidenib, an inhibitor of mutant IDH2 proteins, induces durable remissions in older patients with newly diagnosed acute myeloid leukemia. Leukemia 2019;33(11):2575-84. Abstract
Ragon BK et al. Targeting IDH1 and IDH2 mutations in acute myeloid leukemia. Curr Hematol Malig Rep 2017;12(6):537-46. Abstract
Ritchie E et al. Outcomes with CPX-351 versus 7+3 by baseline bone marrow (BM) blast percentage in older adults with newly diagnosed high-risk/secondary acute myeloid leukemia (sAML). Proc ASCO 2019;Abstract 7042.
Roboz G et al. Ivosidenib (IVO; AG-120) in IDH1-mutant newly-diagnosed acute myeloid leukemia (ND AML): Updated results from a phase 1 study. Proc ASCO 2019;Abstract 7028.
Sasaki K et al. Sorafenib plus intensive chemotherapy improves survival in patients with newly diagnosed, FLT3-internal tandem duplication mutation-positive acute myeloid leukemia. Cancer 2019;125(21):3755-66. Abstract
Short NJ et al. Treatment with a 5-day versus a 10-day schedule of decitabine in older patients with newly diagnosed acute myeloid leukaemia: A randomised phase 2 trial. Lancet Haematol 2019;6(1):e29-e37. Abstract
Shoukier M et al. Activity of venetoclax-based therapy in TP53-mutated acute myeloid leukemia. Proc ASCO 2019;Abstract 7034.
Stein EM et al. Molecular remission and response patterns in patients with mutant-IDH2 acute myeloid leukemia treated with enasidenib. Blood 2019;133(7):676-87. Abstract
Stein EM et al. Enasidenib in mutant IDH2 relapsed or refractory acute myeloid leukemia. Blood 2017;130(6):722-31. Abstract
Stone RM et al. Crenolanib versus midostaurin combined with induction and consolidation chemotherapy in newly diagnosed FLT3 mutated AML. Proc ASCO 2019;Abstract TPS7068.
Stone RM et al. Midostaurin: Its odyssey from discovery to approval for treating acute myeloid leukemia and advanced systemic mastocytosis. Blood Adv 2018;2(4):444-53. Abstract
Stone RM et al. Midostaurin in FLT3-mutated acute myeloid leukemia. N Engl J Med 2017;377(19):1903. Abstract
Tallman MS et al. Acute myeloid leukemia, version 3.2019, NCCN clinical practice guidelines in oncology. J Natl Compr Canc Netw 2019;17(6):721-49. Abstract
van Galen P et al. Single-cell RNA-seq reveals AML hierarchies relevant to disease progression and immunity. Cell 2019;176(6):1265-81. Abstract
Webster JA, Pratz KW. Acute myeloid leukemia in the elderly: Therapeutic options and choice. Leuk Lymphoma 2018;59(2):274-87. Abstract
Weisberg E et al. Comparison of effects of midostaurin, crenolanib, quizartinib, gilteritinib, sorafenib and BLU-285 on oncogenic mutants of KIT, CBL and FLT3 in haematological malignancies. Br J Haematol 2019;187(4):488-501. Abstract
Winer ES, Stone RM. Novel therapy in acute myeloid leukemia (AML): Moving toward targeted approaches. Ther Adv Hematol 2019;[Epub ahead of print]. Abstract
Yalniz F et al. Prognostic significance of baseline FLT3-ITD mutant allele level in acute myeloid leukemia treated with intensive chemotherapy with/without sorafenib. Am J Hematol 2019;[Epub ahead of print]. Abstract
Yogarajah M, Stone RM. A concise review of BCL-2 inhibition in acute myeloid leukemia. Expert Rev Hematol 2018;11(2):145-54. Abstract